Skip to content
EB child talking to an EB doctor.

To reach the clinical stage and beyond

Translating research success into clinical benefit

EB is a rare and diverse group of conditions, with some subtypes classified as very rare. Nevertheless, rapid expansion of knowledge of EB over the past decade creates diverse opportunities for novel products, therapies, and diagnostics. 

EB-ResNet has been established to coordinate research-active EB patient organisations and industry to bring effective, safe, life-changing treatments to EB patients. Four decades of research funding by EB-ResNet members and partners have created the disease knowledge base and clinical networks necessary to de-risk investment in clinical trials and market development.

Find out more about ongoing clinical trials on Epidermolysis Bullosa.

More about clinical trials

In order to bridge the gap between fundamental research and clinical trials we need industry and academic partners.

Clinical development

Find out how EB-ResNet or national groups can cooperate with industry or academic partners.

Partner with EB-ResNet

No clinical trials without patients. How to include patients and their needs as early as possible, to reach clinical endpoints?

How to access EB patients
Back to main navigation